Metraipolis › archive › dc_2969e7dca407

Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer — Europe PMC PMID:41076600

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41076600
DOI
10.1007/s12282-[numero omesso]-6
License (as archived)
solo-consultazione
Archived
2026-11-09T09:38:08.640Z
SHA-256 of the archived text
cd4b7e0c0e7f5824a0d9ba2e75191836e56f88928031e2ec7ae709be4429ad1c
Stable URL of this page
https://metraipolis.com/documento/dc_2969e7dca407

How to cite

Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer — Europe PMC PMID:41076600 — Europe PMC (en), https://europepmc.org/article/MED/41076600 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2969e7dca407 (Metraipolis archive dc_2969e7dca407, sha256 cd4b7e0c0e7f5824a0d9ba2e75191836e56f88928031e2ec7ae709be4429ad1c)
BibTeX
@misc{dc2969e7dca407,
  title = {Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer — Europe PMC PMID:41076600},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41076600},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2969e7dca407; sha256 cd4b7e0c0e7f5824a0d9ba2e75191836e56f88928031e2ec7ae709be4429ad1c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41076600. Agents can read the archived copy with the MCP tool read_document.